New research in mice presented June 11 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 annual meeting touted the success of a new radiopharmaceutical to treat ovarian cancer.
A research team led Mike Zamiara, president of Niowave, used a radioisotope generator system to develop the targeted alpha-therapy Pb-214-TCMC-trastuzumab to treat human epidermal growth factor receptor 2-positive ovarian cancer.
Bioluminescence images overlayed with pictures of mice implanted intraperitoneally with luciferase-positive ovarian cancer cells (SKOV3) before and after treatment with Pb-214-TCMC-trastuzumab. Image courtesy of SNMMI.Zamiara and colleagues said preclinical trials of the treatment showed limited tumor growth and decreasing tumor mass in mouse models with ovarian cancer. They noted that the radiopharmaceutical can be produced in 25 minutes.
